China’s “Guidelines for the Prevention and Treatment of Chronic Hepatitis B” states that. When using nucleoside {acid) analogs for antiviral therapy, e antigen positive patients should take them for at least 2 years and e antigen negative patients should take them for at least 2.5 years and meet the criteria for discontinuation before stopping them. Chronic hepatitis B is a disease that continues to progress and is prone to relapse. If during the treatment process. The actual fact is that you will not be able to get a good deal on your own. If you don’t go to the hospital for a review, it is difficult to achieve the purpose of treatment. Therefore, for the treatment of chronic hepatitis B, it is very important to adhere to treatment and regular review, one without the other. According to the survey. In the process of hepatitis B treatment, nearly two-thirds of patients have stopped taking their own medication. The consequences of random drug discontinuation on the treatment of hepatitis B First, aggravation of the disease liver inflammation aggravated liver function and bad, and even deterioration, liver failure, cirrhosis and liver cancer progress will also be accelerated. Second, treatment goals can not be achieved Hepatitis B virus DNA and e antigen continue to be positive, ALT can not come down, resulting in the inability to stop the drug; the risk of complications such as cirrhosis and liver cancer is greatly increased, and the survival time of patients is shortened. Third, it is easy to develop drug resistance Hepatitis B virus is constantly developing and changing in the body. If the drug is stopped arbitrarily, the hepatitis B virus will not be effectively suppressed and will easily develop drug resistance, which will reduce the efficacy of the drug or make it useless. Adding or switching to other drugs will increase the cost of treatment and the drug resistance of hepatitis B virus, which will make treatment more difficult. Therefore. In the process of chronic hepatitis B treatment, it is crucial to adhere to the medication to achieve the treatment goal as soon as possible. In addition to adherence to treatment. It is also important to have regular follow-up examinations. In the treatment of chronic hepatitis B, we need to check the relevant indicators to see if the disease is under control. It is important to check whether the disease has improved or deteriorated. The patient or doctor may not know if the disease has worsened because the symptoms may not be obvious if the patient is not examined. Secondly, the evaluation of the father should be flogged to predict the efficacy of the medication through the changes in the indicators of hepatitis B, hepatitis B virus DNA, etc., to predict the efficacy of the medication in a subsequent period such as 3 months or 6 months. And about when to stop the drug. Third, to ensure good drug safety drugs in the process of use. Adverse reactions can occur, which is a well-known problem. But how to deal with adverse drug reactions, in the treatment of chronic hepatitis B at the same time, to protect their own safety? In addition to taking the medication according to the doctor’s requirements or instructions, it is also important for the patient to have regular reviews and to maintain good communication with the doctor and follow the doctor’s instructions. The significance of regular check-ups after patients stop taking medication To observe whether the disease has rebounded, and if there are signs of rebound. Consider resuming treatment early. In this way, the chronic hepatitis B disease can be controlled. This will enable the chronic hepatitis B disease to be controlled and the medication to be stopped sooner. Therefore. Whether in the treatment phase or after discontinuation of medication. It should be reviewed regularly. Then, chronic hepatitis B patients in the treatment phase and after discontinuation of drugs. How can we talk about regular review? During the antiviral treatment period, the hepatitis B half and hepatitis B virus DNA should be checked once every 3 months; the liver function should be checked once a month after the start of treatment. The liver function will be checked once a month after the start of treatment, 3 times in a row, and then once every 3 months as the condition improves. After stopping the drug, the hepatitis B hepatitis B virus DNA and liver function will be tested at least once every 2 months within 6 months. After that, they should be rechecked every 3 to 6 months. Follow up for at least 24 months, and if there is any change in the condition during the follow-up. The follow-up interval should be shortened. In summary, for the treatment of chronic hepatitis B, adherence to medication is an effective way to prevent relapse, reduce hepatitis B virus resistance, and achieve treatment goals early. The regular review is of guiding significance for the timely adjustment of the treatment plan, early recovery of patients, early prediction of the efficacy and the safety of patients with medication.